No Data
Atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know
TD Cowen Maintains ATAI Life Sciences(ATAI.US) With Buy Rating
TD Cowen analyst Ritu Baral maintains $ATAI Life Sciences(ATAI.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.1% and a total average return of 7.4% over the pa
Atai Life Sciences CEO Talks Successful Phase 1 Trial of IV Psilocin Formulation – ICYMI | NASDAQ:ATAI, ETR:9VC
Atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,
Atai Life Sciences Co-CEO Says Initial Results From ELE-101 Show Promise in Treating Depression | NASDAQ:ATAI, ETR:9VC
Express News | Cantor Fitzgerald Reiterates Overweight on ATAI Life Sciences